Illumina, Inc. (ILMN)
After hours:
| Previous Close | 215.74 |
| Open | 209.27 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 198.19 - 216.15 |
| 52 Week Range | 173.45 - 371.16 |
| Volume | |
| Avg. Volume | 1,212,222 |
| Market Cap | 31.224B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 46.38 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
- Reuters
Illumina fights EU order to divest Grail
U.S. life science company Illumina on Wednesday took its case to senior EU and national antitrust officials at a closed hearing to argue against an EU antitrust order that it divests cancer detection test maker Grail Inc. Illumina had completed a takeover of Grail in August 2021, without securing European Union regulatory approval. The European Commission ordered Illumina in December to unwind the deal, three months after it had blocked the merger on concerns the deal would stifle innovation.
- Zacks
Illumina (ILMN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
